Logo-bi
Editorial

1. Personalized cell-mediated immunotherapy and vaccination: combating detrimental uprisings of malignancies
Jaleh Barar* ORCID, Yadollah Omidi* ORCID
Bioimpacts. 2015;5(2): 65-69. doi: 10.15171/bi.2015.18
PMCID: PMC4492186     PMID: 26191499     Scopus ID: 84930410369    
Article
PDF
XML
Cited By:
3
0
2
Editorial

2. Made-on-demand, complex and personalized 3D-printed drug products
Karim Osouli-Bostanabad, Khosro Adibkia* ORCID
Bioimpacts. 2018;8(2): 77-79. doi: 10.15171/bi.2018.09
PMCID: PMC6026524     PMID: 29977828     Scopus ID: 85048089691    
Article
PDF
Full Text
XML
Cited By:
26
4
27
Editorial

3. Aptamedicine: a new treatment modality in personalized cancer therapy
Somayeh Vandghanooni, Morteza Eskandani, Jaleh Barar ORCID, Yadollah Omidi* ORCID
Bioimpacts. 2019;9(2): 67-70. doi: 10.15171/bi.2019.09
PMCID: PMC6637218     PMID: 31334037     Scopus ID: 85067455587    
Article
PDF
Full Text
XML
Cited By:
14
2
2
Aptamers (Aps) are short single-strand nucleic acids, which can be used as the therapeutic and targeting agent in advanced drug delivery systems. Conjugation of Aps with other entities (siRNA, toxins, drugs, DNAzyme/Ribozymes) provides advanced multifunctional nanosystems for cancer therapy.
Review

4. Regulation of cell fate by cell imprinting approach in vitro
Farkhonde Hasannejad ORCID, Leila Montazeri, João F Mano* ORCID, Shahin Bonakdar* ORCID, Ahmad ‎ Fazilat
Bioimpacts. 2024;14(3): 29945. doi: 10.34172/bi.2023.29945
PMCID: PMC11199935     PMID: 38938752     Scopus ID: 85194769935    
Article
PDF
XML
Cited By:
1
0
2
Review

5. Cancer treatment comes to age: from one-size-fits-all to next-generation sequencing (NGS) technologies
Sepideh Parvizpour* ORCID, Hanieh Beyrampour-Basmenj, Jafar Razmara* ORCID, Farhad Farhadi, Mohd Shahir Shamsir
Bioimpacts. 2024;14(4): 29957. doi: 10.34172/bi.2023.29957
PMCID: PMC11298019     PMID: 39104623     Scopus ID: 85198900583    
Article
PDF
Full Text
XML
Cited By:
0
0
0

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge